Belgers V, Tolver A, Klein M, Douw L, Niers J, Piil K
Neurooncol Pract. 2025; 12(1):122-130.
PMID: 39917762
PMC: 11798611.
DOI: 10.1093/nop/npae085.
Campbell R, Shaw J, Carlick T, Banks H, Faris M, Jeon M
J Cancer Surviv. 2024; .
PMID: 39405030
DOI: 10.1007/s11764-024-01691-3.
Gardner M, Winter S, Stahl F, Gerstner E, Shih H, Sherman J
J Neurooncol. 2024; 171(2):351-363.
PMID: 39400662
DOI: 10.1007/s11060-024-04850-9.
James E, Wallace M, Chard M, Camicia M, Lutz B, Minns L
J Adv Nurs. 2024; 81(3):1583-1597.
PMID: 39278630
PMC: 11810499.
DOI: 10.1111/jan.16420.
Fehrenbach M, Wilhelmy F, Wende T, Guresir E, Kasper J
J Neurooncol. 2024; 168(1):151-157.
PMID: 38563854
DOI: 10.1007/s11060-024-04657-8.
What do spouse primary caregivers of patients with glioblastoma want medical providers to know? A qualitative thematic reflexive analysis of letters written by primary caregivers from a secret Facebook support group.
Coman D, Chard M, Desautels L, Lutz B, Minns L
BMJ Open. 2024; 14(3):e081783.
PMID: 38479741
PMC: 10936493.
DOI: 10.1136/bmjopen-2023-081783.
Brain Re-Irradiation Or Chemotherapy: a phase II randomised trial of re-irradiation and chemotherapy in patients with recurrent glioblastoma (BRIOChe) - protocol for a multi-centre open-label randomised trial.
Hudson E, Noutch S, Webster J, Brown S, Boele F, Al-Salihi O
BMJ Open. 2024; 14(3):e078926.
PMID: 38458809
PMC: 11145639.
DOI: 10.1136/bmjopen-2023-078926.
Application of Quercetin and its Novel Formulations in the Treatment of Malignancies of Central Nervous System: An Updated Review of Current Evidence based on Molecular Mechanisms.
Jamshidi-Mouselou M, Hashemi A, Jamshidi-Mouselou M, Farkhondeh T, Pourhanifeh M, Samarghandian S
Curr Med Chem. 2024; 31(26):4180-4198.
PMID: 38265392
DOI: 10.2174/0109298673266672231121173432.
Systematization of rehabilitation interventions for neuro-oncological patients using international classification of health interventions: a scoping review.
Petersone A, Karklina A, Berzina G
J Rehabil Med. 2024; 56:jrm12335.
PMID: 38214120
PMC: 10802786.
DOI: 10.2340/jrm.v56.12335.
[Rational treatment of depressive syndromes in brain tumor patients].
Knabbe J, Kowalski T, Seliger C
Nervenarzt. 2023; 95(2):125-132.
PMID: 37861698
DOI: 10.1007/s00115-023-01558-5.
Experiences of work for people living with a grade 2/3 oligodendroglioma: a qualitative analysis within the Ways Ahead study.
Walker H, Rimmer B, Dutton L, Finch T, Gallagher P, Lewis J
BMJ Open. 2023; 13(9):e074151.
PMID: 37770270
PMC: 10546132.
DOI: 10.1136/bmjopen-2023-074151.
influences the prognosis, pathogenesis, and immune microenvironment in patients with lower-grade glioma.
Zhu Q, Liu Z, Cheng X, Liang W, Wang H, Li P
Heliyon. 2023; 9(7):e18185.
PMID: 37519705
PMC: 10372659.
DOI: 10.1016/j.heliyon.2023.e18185.
Repeated awake surgery and quality of life in patients with diffuse glioma: a systematic review and meta-analysis.
Fauvet C, Villain M, Gatignol P
Neurosurg Rev. 2023; 46(1):156.
PMID: 37382692
DOI: 10.1007/s10143-023-02073-6.
Incidence of clinically relevant psychiatric symptoms during glioblastoma treatment: an exploratory study.
Regli L, Huijs S, Pasmans R, Leue C, Dijkstra J, Eekers D
J Neurooncol. 2023; 163(1):185-194.
PMID: 37162667
PMC: 10232638.
DOI: 10.1007/s11060-023-04326-2.
Symptom networks in glioma patients: understanding the multidimensionality of symptoms and quality of life.
Rottgering J, Varkevisser T, Gorter M, Belgers V, de Witt Hamer P, Reijneveld J
J Cancer Surviv. 2023; 18(3):1032-1041.
PMID: 36922442
PMC: 11082018.
DOI: 10.1007/s11764-023-01355-8.
Optimal care of people with brain cancer in the emergency department: A cross-sectional survey of outpatient perceptions.
Waller A, Hullick C, Sanson-Fisher R, Herrmann-Johns A
Asia Pac J Oncol Nurs. 2023; 10(3):100194.
PMID: 36915388
PMC: 10006536.
DOI: 10.1016/j.apjon.2023.100194.
Frequency and burden of potentially treatable symptoms in glioma patients with stable disease.
Rottgering J, Belgers V, Kouwenhoven M, Schuur M, Postma T, Nijboer C
Heliyon. 2023; 9(2):e13278.
PMID: 36798771
PMC: 9925977.
DOI: 10.1016/j.heliyon.2023.e13278.
Toward unraveling the correlates of fatigue in glioma.
Rottgering J, Belgers V, de Witt Hamer P, Knoop H, Douw L, Klein M
Neurooncol Adv. 2022; 4(1):vdac169.
PMID: 36425844
PMC: 9680534.
DOI: 10.1093/noajnl/vdac169.
H2B gene family: A prognostic biomarker and correlates with immune infiltration in glioma.
Jia J, Han Z, Wang X, Zheng X, Wang S, Cui Y
Front Oncol. 2022; 12:966817.
PMID: 36387186
PMC: 9641242.
DOI: 10.3389/fonc.2022.966817.
Targeting Heat Shock Proteins in Malignant Brain Tumors: From Basic Research to Clinical Trials.
Babi A, Menlibayeva K, Bex T, Doskaliev A, Akshulakov S, Shevtsov M
Cancers (Basel). 2022; 14(21).
PMID: 36358853
PMC: 9659111.
DOI: 10.3390/cancers14215435.